FDA Poised to Review Two New Drugs for Type 2 Diabetes

courtesy of

Published 04/01

The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.


Read more

Want more valuable Blood Sugar information?

Join the Search Blood Sugar E-newsletter and you'll get the latest articles and resources sent straight to your inbox.

Simply fill in the form below and you'll be set to receive your first newsletter within the next week!

First Name:

Last Name:

Email Address: